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Edited by Bernd HelmsAbstract The cell biology of intracellular pathogens (viruses,
bacteria, eukaryotic parasites) has provided us with molecular
information of host–pathogen interactions. As a result it is
becoming increasingly evident that lipids play important roles
at various stages of host–pathogen interactions. They act in ﬁrst
line recognition and host cell signaling during pathogen docking,
invasion and intracellular traﬃcking. Lipid metabolism is a
housekeeping function in energy homeostasis and biomembrane
synthesis during pathogen replication and persistence. Lipids of
enormous chemical diversity play roles as immunomodulatory
factors. Thus, novel biochemical analytics in combination with
cell and molecular biology are a promising recipe for dissecting
the roles of lipids in host–pathogen interactions.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Infectious diseases are a continuous burden on global health.
AIDS, Malaria and Tuberculosis are the top three infectious
diseases by scale of mortality. While these diseases typically
are limited to endemic areas, other forms of infections, such
as avian ﬂu or the SARS, have been posing immediate threats
based on localized outbreaks followed by rapid global spread-
ing. All of these infectious diseases are caused by intracellular
pathogens, enveloped viruses, mycobacteria and eukaryotic
parasites.
The biosynthesis of mammalian lipids is fairly well under-
stood. This is not at all the case however for pathogen lipids
where many of the genes which encode for lipid enzymes have
not been identiﬁed and characterized in detail. In addition, de-
spite many decades of biochemical research, we only have a va-
gue picture of membrane and cell wall composition of many
pathogens and the role of lipids in microbial pathogenesis
[1,2]. This review should act to stimulate a thought process
on the potential functions of lipids during interaction of
important intracellular pathogens with their mammalian (hu-
man) host cells. In an attempt to conceptualize a format for fu-
ture update and reference the host–pathogen interaction
process is divided into various steps (Fig. 1) at which diﬀerent*Fax: +65 6779 1453.
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doi:10.1016/j.febslet.2006.07.007classes of lipids [3] have been shown to play a role (Table 1).
Eicosanoids and derivatives, well known immunomodulatory
lipids [4], are not discussed in detail here. Instead the focus lies
in membrane components and lipids involved in energy
homeostasis.2. A lipidomic view of pathogen replication cycles
Extracellular (free) forms of pathogens depend on lipids for
structural and functional integrity (Fig. 1, stage 1). Uptake of
pathogens is accompanied by general phenomena including
re-organization of the cytoskeleton, membrane ruﬄing and
invagination at the site of pathogen entry. Obviously, these
processes are orchestrated, in part, by signaling cascades
including lipid kinases, phosphatases and lipases. What is not
evident is the precise interconnectivity between pathogen lipid
metabolism and host lipid metabolism (Fig. 1, stages 2–5).
2.1. Enveloped viruses (human immunodeﬁciency virus)
Enveloped viruses are critically dependent on their lipid shell
which is evidenced by the high sensitivity to detergent. Indeed,
delipidation of viruses is used in novel antiviral therapeutics
[5]. It is intriguing that, so far, not much interest has been de-
voted to the lipid inventory of viruses, much in contrast to vir-
al genomes and proteins. This is largely due to the fact that
only very few virus encoded lipid enzymes are known [6]. In-
stead, viruses derive their lipids from the host. Biochemical
analysis of puriﬁed viruses shows that certain classes of lipids,
even speciﬁc molecular species, are present and enriched in vir-
al particles [7,8]. It will be interesting to see how lipids act at
the molecular level during virus particle formation and propa-
gation (Fig. 1, stage 1).
The precise signaling reactions at docking sites remain
unclear yet recent observations suggest that binding of murine
leukemia virus is followed by rapid, actin-mediated movement
along ﬁlopodia [9]. Pathogen recognition at the cell periphery
might be a trigger event that leads to clustering of lipids [10]
and proteins at the site of docking, followed by signaling
(e.g. via protein kinases and lipid kinases) and subsequent
uptake. Phosphatidylserine and (complex) glycolipids have
been implicated but the precise assembly of such ligand–recep-
tor pairs remains poorly understood. It will be interesting to
learn whether lipids act as co-factors to the well studied
protein–protein interactions that mediate viral docking. It is
conceivable that such interactions play a role given the high
density of epitope-rich glycolipids on mammalian cell surfaces
(Fig. 1, stage 2).blished by Elsevier B.V. All rights reserved.
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Implications of diﬀerent lipid classes at various steps of host–pathogen inter
Stage
(Fig. 1)
Enveloped viruses (e.g. HIV) Bacteria (e.g. myco
1 Mycolic acids and
impermeable layer
plasma membrane
mycobacteria [80,8
Growth state depe
metabolism of trig
mycobacteria in vi
Viral envelopes are enriched in
sphingomyelin [8,86]
Envelope cholesterol is critical for
structure and infectivity [87–89]
2 Phosphatidylserine stimulates entry of
enveloped viruses [90,91]
Mannose receptor
ManLAM mannos
mycobacteria and
phagocytosis [92]
(Complex) glycolipids act as receptors for
viral envelope proteins [93]
Elevated levels of ceramide and GM3
confer resistance to HIV type 1 fusion
[94,95]
Lipid (A) [22] reco
TLR receptors [56,
3 Signaling via lipid kinases is activated
during viral entry [97,98]
Glycolipids promote CD4-dependent
fusion of HIV [99,100]
Cholesterol in target membrane is
required for fusion and infection [101,102]
Cholesterol is requ
of mycobacteria in
macrophages [103]
N
ER
Golgi
1
2
3
4
5
Fig. 1. Stages of host–pathogen interactions. The cartoon illustrates in
general terms the various stages of host–pathogen interactions which
are discussed in the text. Numerous roles of lipids, both of pathogen as
well as of host origin, are summarized in Table 1. 1, Extracellular/free
state; 2, docking; 3, invasion/uptake; 4, intracellular state/persistence/
fusion/replication; 5, budding/escape from host cell.
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many intracellular pathogens. This is also the case for envel-
oped viruses, the majority of which enter via clathrin mediated
endocytosis (human immunodeﬁciency virus, HIV; vesicular
stomatitis virus, VSV) or caveolae/raft mediated uptake (e.g.
Simian Virus 40, SV40). The roles of lipids in these uptake
processes has been studied intensively and phosphorylated
forms of phosphatidylinositol (GPIns), the phosphoinositides
(PIs), cholesterol and sphingomyelin have been critically impli-
cated in clathrin- and caveolae-mediated endocytosis (Fig. 1,
stage 3).
There is growing evidence that lipids play an important role
in the regulation of the infection cycle of enveloped viruses, in
particular during entry, packaging, and release from the host
cell [11]. Genomic analysis of the early host response to hepa-
titis C virus infection revealed that a large number of genes in-
volved in lipid metabolism are diﬀerentially regulated
underscoring the hitherto unappreciated important role of lip-
ids in viral life cycles [12]. Implicated functions range from fu-
sion of endosomal membranes [13] to transcriptional control
of viral mRNA [14], thus spanning a wide range of biological
activities. Hepatitis C virus RNA replication requires the syn-
thesis of fatty acids. Addition of exogenous saturated fatty
acyls to cells leads to increased transcription, whereas polyun-
saturated fatty acyls have the opposite eﬀect [15]. The mecha-actions
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Table 1 (continued)
Stage
(Fig. 1)
Enveloped viruses (e.g. HIV) Bacteria (e.g. mycobacteria) Apicomplexa (e.g. Toxoplasma,
Plasmodium)
4 Fatty acyl synthesis is required for
Hepatitis C virus RNA replication [12,15]
Intracellular growth and
virulence of listeria require host-
derived lipoic acid [105]
Anti type II FAS inhibitors (herbicides
and antibiotics) inhibit apicomplexa [107]
FA
Geranylgeranylation is required for
Hepatitis C virus RNA replication [104]
Trehalose mycolates induce a
proinﬂammatory cascade that
inﬂuences granuloma formation
[106]
Isocitrate lyases (ICL1 and ICL2)
are required for intracellular
replication [31]
Triacylglycerol formation is essential for
intraerythrocytic replication of P.
falciparum [108–110]
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Lysobisphosphatidic acid and
phosphoinositides regulate release of VSV
nucleocapsid into cytoplasm [13]
SigD/SopB is a type III bacterial
derived phosphoinositide
phosphatase [29,112]
Molecular species of phosphatidylcholine
and phosphatidylethanolamine are
altered in host plasmamembrane after
Plasmodium infection [116]
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Ethanolamine phospholipids required for
Sindbis virus production [111]
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of lipids [27,113]
Growth arrest of Plasmodium [117] and
Toxoplasma [85] by disruption of
phosphatidylcholine synthesis
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membrane phospholipids for activity [14]
Phosphatidylinositol mannosides
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endosomes with mycobacterial
phagosomes [30]
Glycosylated
phosphatidylinositol causes
phagosome maturation arrest
[114]
SapM, a mycobacterial derived
phosphatase hydrolyses PI3P
contributing to inhibition of
phagolysosome maturation [115]
Sphingosine 1-kinase is recruited
to nascent phagosomes [118]
Inhibition of sphingolipid biosynthesis in
T. gondii blocks replication [119]
SP
Sphingomyelin metabolism important for
P. falciparum development [120]
Inhibition of cholesterol biosynthesis
inhibits Hepatitis C virus RNA
replication [15]
Inhibition of cholesterol acquisition by
the host lowers T. gondii replication [40]
ST
Cholesterol esteriﬁcation essential for
optimal T. gondii proliferation [121,122]
Isopreonoid synthesis inhibitors with
anti-malarial [123] and anti-T. gondii
activity [124]
PR
Block of protein farnesylation as
antiapicomplexan therapies [125]
5 Unsaturated fatty acids block HIV
budding [126]
Mycobactin mediates iron supply
within macrophages [32]
FA
Aﬃnity of HIV Gag protein is regulated
by myristoyl switch [127]
Presentation of
glycerophospholipids, sulfolipids
and mycolates via CD1 receptors
[58,132,133]
GP
Golgi-derived viruses have diﬀerent phos-
pholipid (incl semilysobisphosphatidic
acid) composition depending on the
precise site of budding [7,128]
HIV-like particle assembly is regulated by
inositol phosphates [129]
HIV-1 Gag targeting is regulated by PIP2
[130]
Vaccinia virus envelope protein p37 has
lipase activity [131]
Nef transports cholesterol to site of HIV
budding [134]
ST
Budding occurs from glycolipid-enriched
membrane lipid rafts [8,135–137]
Table summarizing the reported involvement of lipids, both from the host as well as the pathogen, during various stages of host–pathogen interaction
(Fig. 1). Lipids are classiﬁed according to Fahy et al. [3]. FA, fatty acyls (e.g. oleic acids, prostaglandins); GL, glycerolipids (e.g. triacylglycerol); GP
glycerophospholipids (e.g. phosphatidylinositol); SP, sphingolipids (e.g. sphingomyelin, ceramide); ST, sterol lipids (e.g. cholesterol); PR, preno
lipids (e.g. menaquinone); SL, saccharolipids (e.g. lipid A).
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dent of signaling via nuclear LXR receptors.
The coordinated assembly of viral components and the re-
lease of functional particles from the host are ﬁnal steps of
viral replication (Fig. 1, step 5). Viruses are thus excellent
tools to probe the lipid composition of the membrane site
where budding occurs. Viruses which form on intracellular
membranes (e.g. vaccinia at the Golgi apparatus) carry lipids
which are indicative for these organelles (e.g. lysobisphos-
phatidic acids) [7]. Cell surface packaged viruses (such as
HIV in most cases) are rich in cholesterol and sphingolipids
[8]. This has implications for the properties of the envelope
membrane. The envelope of HIV, for example, was found
to be more ordered than that of the producer cell on average
[16].
2.2. Pathogenic bacteria (Mycobacteria, Salmonella)
Mycobacterium tuberculosis is the causative agent of TB.
With respect to lipids, it is unique among bacteria since it
has approximately 250 lipid enzymes in its genome (compared
to only 50 in Escherichia coli) [17], and an unusually high num-
ber of distinct (glyco)lipids in its cell membrane and wall [18].
The natures of major components are known. However, eluci-
dation of the precise chemical composition of many lipid spe-
cies and more importantly their biosynthetic pathways,
transport [19] and dynamics leaves enormous room for further
investigations. Such more detailed knowledge will enhance the
drug development process which classically has been targeting
cell wall biosynthesis.
Approaches which target speciﬁcally the delicate molecular
machinery employed by bacteria during interactions with
their host will add new ways of interfering with pathogenic
bacteria [20,21]. Among those are many lipid related pro-
cesses (Fig. 1, step 2). One of the classical ligands for Toll
like receptors (TLR) is the lipid A portion of lipopolysaccha-
ride (LPS), a bacterial glycolipid [22]. Many of the TLR bindGPIns(16:0/TSA)
GPIns(16:0/18:1)
A
C
B
D
Fig. 2. Molecular species of mammalian and mycobacterial inositol lipids. P
(GPIns) found in mammalian cells, while panels C and D display structurally
with palmitoyl (C16:0) and oleoyl (C18:1) fatty acyls [GPIns(16:0/18:1)]. (B
stearic acid (C18:0) and arachidonic acid (C20:4), GPIns(4,5)P2 (18:0/20:4). In
in the sn-2 position (box in A) and reversible phosphorylation of inositol h
phosphoinositides (circles in B). (C) GPIns with palmitic acid and tuberculos
acid is a marker for mycobacteria and in addition to GPIns is found in other p
GPIns (16:0/TSA) with two mannose residues (circles) on the inositol headgr
the envelope of mycobacteria and are bioactive during phagocytosis.lipid structures. Thus it can be expected that the advances
made in the systems biology of TLRs [23], and chemical anal-
ysis of naturally occurring forms of LPS [24] will bring to-
gether knowledge from diﬀerent ﬁelds in order to
understand better the molecular mechanisms of pathogen rec-
ognition.
As for viruses, uptake of bacteria (Mycobacteria, Salmo-
nella) occur at specialized membrane microdomains. This
phagocytic process shares some similarity with endocytosis
of viruses. A common strategy for bacteria (as well as eukary-
otic pathogens, see below) is to avoid the degradative environ-
ment of lysosomes. In order to achieve this goal, these
pathogens have developed sophisticated molecular machinery
which interferes with host cell signaling, cytoskeletal rear-
rangements and membrane traﬃcking. The mechanisms em-
ployed include lipid and calcium signaling, small GTPase
function, and are mediated by eﬀector molecules which are
introduced (e.g. via type III [25] or type IV [26] secretion) or
released [27] by the pathogens during invasion of the host
[20,21]. It should be noted that while many pathogens remain
contained in a large (parasitophorous) vacuole (Toxoplasma,
mycobacteria) others escape into the cytosol where they mi-
grate using tails of cytoskeletal matrix (e.g. Trypanosoma cruzi)
[28].
This concept of molecular mimicry in order to disguise and
trick the host is also reﬂected at the level of lipid metabolism.
Salmonella typhimurium uses its SigD/SopB phosphatase to
interfere with phosphoinositide metabolism of the host. This
leads to the generation of a spacious replicative vacuole and
blocking of maturation into phagolysosomes [29]. Intracellular
bacteria release chemically distinct mixtures of lipids which
interfere with membrane traﬃcking. It is intriguing that these
biologically highly active compounds share some structural
similarity to endogenous lipids which act as prominent signal-
ing molecules in our body (Fig. 2). Mannosylated forms of
GPIns (Fig. 2D), reminiscent to the doubly phosphorylatedGPIns(4,5)P2 (18:0/20:4)—  PIP2
[Man]2GPIns (16:0/TSA)—PIM2
anels A and B show representative examples of phosphatidylinositols
reminiscent molecules found in mycobacteria. (A) Structure of GPIns
) Structure of phosphatidylinositol-bis-phosphate, GPIns(4,5)P2, with
mammalian cells fatty acyls with unsaturation are preferentially found
eadgroup of GPIns leads to the generation of seven naturally known
tearic acid (TSA, 10-methyl stearic acid, C19:0, box). Tuberculostearic
hospholipids as well as in mannosylated forms of GPIns (panel D). (D)
oup [Man]2GPIns (16:0/19:0) (PIM2). PIMs are important structures in
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sion and phagosome maturation [30] (Fig. 1, stage 4). Often
the lipid mimics employed by mycobacteria do not occur in
the host cells and thus represent attractive sites for interven-
tion.
The interaction between bacteria and their host at intracellu-
lar stages indeed deserves special attention. The parasites need
to acquire resources from their hosts in order to survive, rep-
licate or persist. Much of our knowledge in this area stems
from research conducted on eukaryotic parasites (see below).
There is increasing awareness however, also in the ﬁeld of bac-
teriology, that supply with energy and resources is an aspect
which might have been misjudged in its importance in the past.
Energy production via beta oxidation of fatty acyls, using the
glyoxylate cycle enzymes isocitrate lyases, is required for intra-
cellular replication of mycobacteria [31]. Iron is required for
growth of bacteria. Mycobacteria have thus developed sidero-
phore based systems which supply them with iron. Mycobactin
is one of these iron chelators and in infected cells localizes at
cytosolic lipophilic structures in close proximity to the intracel-
lular vacuoles which harbor bacteria [32,33]. The lipid tail
of the mycobactin lipopeptide is likely to play an important
anchor role during traﬃcking and localization of the iron
carrier.
It should be stressed that commonly accepted wisdoms of
bacterial lipidomes will have to be revisited. Phosphatidyleth-
anolamine, phosphatidylglycerol and cardiolipin are major
and important components. However, diﬀerent classes of bac-
teria have developed very complex sets of chemically diverse
lipid components to complement this basic inventory. The lip-
ids of mycobacteria are a leading example but other clinically
important pathogenic bacteria such as Helicobacter pylori are
likely be investigated with enhanced scrutiny in this respect
[34].
2.3. Eukaryotic parasites – apicomplexa
Apicomplexan parasites (e.g. Toxoplasma, Plasmodium)
cause major diseases in animals and humans. Toxoplasma gon-
dii is a particularly well studied member of apicomplexans due
to the relative ease of genetic manipulation and cultivation in
the laboratory. It is thus not surprising that much of what we
know about apicomplexan lipids originates form work on T.
gondii.
Entry of eukaryotic parasites remains less well understood
compared to endocytosis and phagocytosis of viruses and bac-
teria. In the case of apicomplexa this is due in part to the rapid
kinetics of the invasion process. GPI anchored proteins in the
host [35,36] or the parasite [37] act as receptors for Plasmodium
falciparum attachment and entry. Targeting of the GPI anchor
structure is indeed an avenue which is explored for anti-mala-
rials with novel modes of action. The rhoptry, a specialized
secretory organelle of Toxoplasma, discharges its content
during entry into host cells. Rhoptries contain high levels of
cholesterol (which Toxoplasma does not synthesize itself) but
it is not precisely clear how this relates to function. It is intrigu-
ing that the same lipid which is required for the much slower
endocytic and phagocytic uptake of viruses and bacteria is also
implicated in the explosive generation of a membrane envelope
around invading Toxoplasma. Host cholesterol, rather than T.
gondii derived cholesterol, however, regulates entry [38]. With
the rapid accumulation of knowledge in the ﬁeld of multivesic-
ular body (MVB) formation and viral budding, it can be ex-pected that more light will be shed also on the pathway of
rhoptry biogenesis. It has been hypothesized that the latter is
reminiscent of MVB formation and includes secretory and
endocytic pathways and adaptor based vesicular components
(e.g. AP-1 and vps4) [39].
As obligate intracellular pathogens Plasmodium and Toxo-
plasma are dependent on nutrient access [40]. Phospholipid
and neutral lipids are currently at a center stage of attention
at intracellular stages of Toxoplasma but also of other para-
sites which feed small molecular metabolites from their hosts
(Table 1). Neutral lipids (triglycerides, sterols and sterol esters)
are stored in ‘lipid bodies’ which are observed at the ultrastruc-
tural level as droplets both in the parasites as well as in the
cytosol of the host. The biogenesis of lipid droplets has at-
tracted much interest in recent years because of their potential
role in a variety of organisms and conditions on top of the
more established function in adipose tissues [41]. In fact, they
are now considered bonaﬁde organelles with distinct metabo-
lism. Their biogenesis is not fully understood and follows dif-
ferent pathways in bacteria and eukaryotic cells [42].
Triglycerides have been described in Toxoplasma [43] and in
mycobacteria from sputum of patients with TB [44]. Function-
ally, the fatty acyls stored in triglycerides of fat bodies might
be used (i) as a source of energy (e.g. upon resuscitation from
dormant conditions) or (ii) as building blocks for membrane
lipid synthesis during phases of active replication (see also be-
low). Delineation between these options will be an important
goal in future research. In the case of Plasmodium for example
the usage of fatty acyls as a source of energy might not be very
likely since its genome seems to lack homologies of enzymes in-
volved in beta-oxidation [45]. In addition, the role of tricar-
boxylic acid cycle enzymes in the Plasmodium mitochondrion
is unclear [46].3. Novel approaches and tools to study the role of lipids during
host–pathogen interactions
Over the past decade, research using genetic, cell biological
and biochemical approaches has led to an enormous increase
in molecular and mechanistic insight into interaction of patho-
gens with their hosts. Cell biological investigations, driven of-
ten by microscopy as a major technique, of fundamental
microbiology proved particularly insightful since they added
temporal and spatial elements to host–pathogen interactions.
Initially, like in many other ﬁelds of biomedical research, the
main focus was on identiﬁcation of genes and proteins re-
quired for activity. Based on these ﬁndings there is now in-
creased awareness that lipids, both of host as well as
pathogen origin, play critical roles in regulating pathogen sta-
bility, entry into host cells as well as replication and persis-
tence. Advancements in research and development are now
fueled by increasing interests aimed at discovery of novel
therapeutic interventions against major infectious diseases
[47,48].
3.1. Cell and chemical biology
Classical experiments using pathogens as tools to investigate
principles of membrane traﬃcking laid the foundation for an
overlap between the ﬁelds of cell biology and microbiology
[49]. These studies were complemented with biophysical char-
acterization of membrane fusion and structural work on the
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(radio- and ﬂuorescently)-labeled lipids and optical probes
for localization of signaling lipids in living cells (e.g. PH do-
main fusions to green ﬂuorescent protein) have provided us
with information on early signaling events during pathogen en-
try and uptake of lipid (precursors) during replication. Rapid
accumulation and degradation of phosphoinositides was fol-
lowed using protein probes speciﬁc for PI(3)P, PI(4,5)P2,
PI(3,4,5)P3, and diacylglycerol, alone or in combination, in liv-
ing cells [29,50]. Careful comparison with morphological
observations of endosomal membranes linked these ‘waves’
of lipid metabolism to functional activity which, in these cases
were attenuation or arrest of phagosomal maturation, with a
beneﬁt for the pathogen [51].
In case of virus fusion certain lipids are now known to be
important co-factors for docking and release at the cell surface
as well as in intracellular compartments (Table 1). The precise
molecular arrangements of lipid–protein complexes are not
known however. It is conceivable that future developments
of ‘fusion/entry-inhibitors’ will include a substantial amount
of structure–function based considerations on lipid–peptide
interactions. Some of these insights will come from structural
analysis of fusion complexes but also high resolution mapping
of small molecule inventories in viruses [8]. Virus-like particles
(virosomes) with traﬃc and fusion characteristics similar to
real viruses can be used for targeted delivery, enhanced trans-
fection, and vaccine development [52,53].
Antibodies or protein modules speciﬁc for other proteins or
ligands are traditional tools in cell biological research. While
many lipid binding modules are known, their speciﬁcity is re-
stricted mainly to phosphoinositides [54]. CD1, TLR and
ML domain containing proteins have been shown recently to
bind to various forms of complex lipids with a functional link
to immunology [55–57]. The basic principle which governs
speciﬁcity of recognition is not clear and in some cases is reg-
ulated by ‘chaperone-like’ proteins (e.g. saposins during CD1
loading [58], or ML proteins as co-factors of TLR in lipid A
recognition [57]).
The antibody response which occurs in patients with AIDS
is generally ineﬀective against the virus. Typically observed
anti-lipid reactivities in patients infected with HIV include
anti-cardiolipin, as well as anti-phosphatidylinositol and
anti-phosphatidylserine antibodies [59,60]. The signiﬁcance of
this response is not clear and could involve reactions to cell
debris (e.g. apoptotic cells and mitochondria which expose/lib-
erate cardiolipin and phosphatidylserine). Interestingly, rare
human antibodies which neutralize HIV are also reactive
against cardiolipin [61].
Surprisingly, in fact, very few speciﬁc antibodies against lip-
ids are currently known. In addition to the above there are a
few diseases, mainly inﬂammatory disorders such as multiple
sclerosis, systemic lupus erythematosus and anti-phospholipid
syndrome, which are accompanied by lipid directed antibodies.
Lipid microarrays (immobilized lipid chips) were recently used
to detect antibodies against sulfatides, sphingomyelin and oxi-
dized lipids from cerebrospinal ﬂuids of patients with multiple
sclerosis [62]. Caution is needed however in the use and expec-
tations of these anti-lipid antibodies due to the fact that they
are directed against serum proteins which bind phospholipids
[63]. It can be anticipated that more anti-lipid antibodies,
hopefully with better speciﬁcities, will be identiﬁed in the fu-
ture due to (i) the investigations of the immunology of lipid re-lated diseases and (ii) increased availability of milligram to
gram quantities of pure and synthetic (glyco)lipids with high
bioactivity [64,65].
3.2. Lipid proﬁling
Analysis of pathogen lipids in not something new. Major ad-
vances in analytical biochemistry have however added new
momentum to such analysis. Liquid chromatography and mass
spectrometry are fueling the ﬁeld of lipidomics as major tech-
nological platforms. These approaches allow detection, char-
acterization and quantiﬁcation of many diﬀerent classes of
lipids, even though it is currently not possible to capture the
full ‘lipidome’ of a cell or tissue in one single experiment.
The large body of biochemical information of lipid inventories
(e.g. of mycobacteria) is now being used to investigate the de-
tails of lipid biosynthetic enzymes and lipid transporters. This
work will help to identify pathogen speciﬁc metabolic path-
ways.
Sphingolipids exist in diﬀerent forms in eukaryotic cells
(most bacteria do not synthesize sphingolipids though there
are exceptions). In mammalian cells, sphingomyelin and glyco-
sphingolipids are predominant forms of sphingolipids, whereas
in plants, yeast and kinetoplastids these lipids typically carry
inositol-glycosides on the ceramide backbone. De novo bio-
synthesis of sphingolipid has only very recently been described
in T. gondii [66]. The precise chemical composition of inositol
containing sphingolipids as well as methods for their detection
are just being determined [67,68]. Mass spectrometry based
analysis will thus help to understand better the inventory of
pathogens with respect to bioactive lipids and their metabolism
during interaction with the host. The apicoplast is a specialized
organelle which has received lot of attention as a potential site
of intervention in anti malaria control [69]. This organelle is
essential for parasite survival and is not present in mammalian
host cells. Since the apicoplast is a relict form of chloroplasts,
some, but not all metabolic pathways are known. Several of
the metabolic pathways, including lipid metabolism, seem to
be fundamentally diﬀerent from those found in human hosts
[69].
High resolution analysis of puriﬁed parasites will also help
to learn more about how pathogens use their chemical compo-
sition to protect themselves during transmission within a host
or from host to host. This could point to certain classes of
lipids as major contributors of pathogenicity. Blood stream
forms of Trypanosoma brucei for example are enriched in ether
GPEtn and GPSer [70]. In these lipids the fatty acyls are bound
to the glycerol backbone (typically in the sn-1 position) via an
ether rather than ester bond. In some tissue and cell types ether
lipids exist in considerable amount with their more common
ester analogs. Platelet activating factor is a prominent repre-
sentative of this class of lipids. Ether lipid analogs are used
in antiviral therapy but their mechanism of action remains un-
known [71]. It is possible that the elevated presence of ether
lipids in free forms of pathogens might be related to a role
in antioxidative protection. The control of the redox balance
must be a challenge for pathogens as they travel from host
to host. Indeed, redox cyclers have been proposed as tools to
target viral cholesterol [72].
Identiﬁcation of unique lipid entities with biological activity
is an enormously promising area in infection biology and
immunology. Biochemical fractionation of bacterial extracts
followed by functional assays and analytical chemistry helped
M.R. Wenk / FEBS Letters 580 (2006) 5541–5551 5547to identify glycolipids which act as ligands for CD1 receptors,
elicit proinﬂammatory cytokines [73] and which represent
hypervirulence factors [74–76]. Given the complexity of lipids
in mycobacteria but also in eukaryotic pathogens this is a
promising approach which is likely to lead to the discovery
of many more lipid structures and their biological activities.
A unique feature of many intracellular parasites is revolving
life cycles in diﬀerent organs of the host. Thus, it is possible
that the regulation of various steps of parasite replication
might depend, at least in part, on diﬀerences in lipid levels be-
tween organs. The appearance of an enveloped virus particle
depends on the precise nature of the host cell and the site of
budding. The lipid shell of HIV may be diﬀerent between virus
particles that originate from intracellular membranes as com-
pared to those that bud from the cell periphery. Characteristics
of the glycosylation apparatus between diﬀerent host cells will
aﬀect decoration of proteins and lipids with sugar moieties.
Thus a virus particle is likely to ‘look’ quite diﬀerent at various
stages of replication in the vector and the host. Metabolite
proﬁling approaches will make important contributions in
deciphering such diﬀerences.
‘Pathogen lipid proﬁles’ are the starting point for tests of
functional relevance (pathway discovery [47]). They are also
valuable diagnostic tools for monitoring of replication in lab-
oratory animals (during the development of new medications)
and in clinical isolates [77]. In a world of unprecedented mobil-
ity of man and pathogens, the speed of detection and develop-
ment of eﬀective vaccines, becomes a critical element in the
control of disease outbreaks. Finally, novel diagnostics also
need to be ‘bush-proof’ since many of the diseases discussed
above are primarily diseases which occur in rural (tropical)
areas which are medically and technologically poorly devel-
oped. Multi-metabolite readouts or kits for facile detection
of pathogen related lipids (e.g. based on antibodies, see above)
might represent important future options.
A major problem in many infectious diseases is latency. In
case of a virus, this relates to inactivity in replication and
maintenance of the viral genome. In case of pathogens which
have energy metabolisms of their own, latency is a state of
low metabolic inactivity. This is of course intimately linked
to carbon/lipid metabolism. Comparative lipidomic proﬁling
of pathogens in diﬀerent physiological conditions (e.g. grow-
ing versus non-replicating mycobacteria) will help to identify
pathways which may represent potential sites for therapeutic
interventions. There is an urgent need to understand better
the details of metabolically inactive conditions in particu-
lar under conditions which reﬂect the environment in vivo
[78,79].4. Conclusions
Cell biology of microbial pathogenesis has opened many
doors for future research into the role of lipids in host–patho-
gen interactions. These interactions are very complex, dynamic
and involve a multitude of mechanisms at diﬀerent stages of the
replication cycle. Lipids in host–pathogen interactions, play a
role (i) as structural components (e.g. mycolic acids), in (ii) rec-
ognition (e.g. LPS), (iii) intracellular traﬃcking (e.g. PIM), and
(iv) energy and resource homeostasis during reproduction (e.g.
host lipids are building blocks, mycobactins, etc.). Many diﬀer-
ent chemical forms of lipids are involved ranging from fattyacyls, glycerolipids, glycerophospholipids, sphingolipids, ster-
ols and prenyl lipids making this a true heaven for lipidomic
discovery. Novel approaches for lipid analysis in combination
with the cell and molecular biology will help to dissect the com-
plicated lipid signaling during host–pathogen interactions for
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